277 related articles for article (PubMed ID: 34783972)
1. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis.
Healy BC; Zurawski J; Chitnis T; Weiner HL; Glanz BI
Qual Life Res; 2022 Jun; 31(6):1799-1805. PubMed ID: 34783972
[TBL] [Abstract][Full Text] [Related]
2. [Information processing speed and influential factors in multiple sclerosis].
Zhang ML; Xu EH; Dong HQ; Zhang JW
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
4. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
Chataway J; Murphy N; Khurana V; Schofield H; Findlay J; Adlard N
Curr Med Res Opin; 2021 Jun; 37(6):995-1004. PubMed ID: 33733976
[No Abstract] [Full Text] [Related]
5. Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.
Sumowski JF; Leavitt VM
Arch Phys Med Rehabil; 2014 Jul; 95(7):1298-302. PubMed ID: 24561056
[TBL] [Abstract][Full Text] [Related]
6. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
[TBL] [Abstract][Full Text] [Related]
8. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
Cavallari M; Palotai M; Glanz BI; Egorova S; Prieto JC; Healy BC; Chitnis T; Guttmann CR
Mult Scler; 2016 Dec; 22(14):1841-1849. PubMed ID: 26920374
[TBL] [Abstract][Full Text] [Related]
9. Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis.
Okada K; Kakeda S; Tahara M
Intern Med; 2022 Nov; 61(21):3181-3187. PubMed ID: 35400704
[TBL] [Abstract][Full Text] [Related]
10. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
12. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
13. Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.
El Ayoubi NK; Sabbagh HM; Bou Rjeily N; Hannoun S; Khoury SJ
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229190
[TBL] [Abstract][Full Text] [Related]
14. Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
Conway DS; Thompson NR; Meng X; Johnson K; Fox RJ
Mult Scler; 2021 Apr; 27(5):742-754. PubMed ID: 32672101
[TBL] [Abstract][Full Text] [Related]
15. Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US National Health and Wellness Survey data.
Le HH; Ken-Opurum J; LaPrade A; Maculaitis MC; Sheehan JJ
BMC Neurol; 2024 Feb; 24(1):51. PubMed ID: 38297247
[TBL] [Abstract][Full Text] [Related]
16. Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis.
Herring TE; Alschuler KN; Knowles LM; Phillips KM; Morean WM; Turner AP; Ehde DM
Mult Scler Relat Disord; 2021 Sep; 54():103109. PubMed ID: 34237561
[TBL] [Abstract][Full Text] [Related]
17. Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS.
Ahvenjärvi H; Niiranen M; Simula S; Hämäläinen P; Surcel HM; Remes AM; Ryytty M; Krüger J
Mult Scler Relat Disord; 2023 Sep; 77():104861. PubMed ID: 37442075
[TBL] [Abstract][Full Text] [Related]
18. Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes.
Theodorsdottir A; Nielsen HH; Ravnborg MH; Illes Z
Mult Scler Relat Disord; 2023 Mar; 71():104550. PubMed ID: 36842312
[TBL] [Abstract][Full Text] [Related]
19. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis.
Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN
Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673
[TBL] [Abstract][Full Text] [Related]
20. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
